News
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026.
Swipe to discover more
-
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis. -
Lab Professionals Celebrating Lab Professionals: A Look Behind the bioMérieux Bench
Behind every diagnosis is a lab professional who made it possible, yet their expertise and dedication rarely get the recognition they deserve. And with the ever-evolving healthcare landscape, just trying to keep up can feel like a challenge.
-
Predicting Sepsis-Related Shock Earlier: How AI Could Transform Critical Care
In the ICU, minutes count — particularly for patients with sepsis, where a sudden drop in blood pressure can signal a dangerous turn. If care teams can see that change coming, even by a couple of hours, they can prepare, personalize treatment, and potentially prevent a crisis. That’s where interpretable, clinically grounded AI can help — turning routine hospital data into early warning signs.
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19